Semaglutide 2.4 mg

Novo Nordisk’s SELECT Trial Shows Semaglutide 2.4 mg Cuts Cardiovascular Risk in Overweight and Obese Adults

(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This…

9 months ago